Valink Therapeutics vs Vinci
Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical-stage ADC biotech with ValiLinker site-specific conjugation technology; VLT-03 in Phase I for solid tumors and VLT-01 for brain metastases with $20.5M raised.
About
Valink Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for solid tumors using its proprietary ValiLinker technology — a site-specific conjugation platform that precisely attaches cytotoxic payloads to antibodies at defined positions, improving ADC stability, homogeneity, and therapeutic index compared to conventional random-conjugation approaches. Founded in 2020 and headquartered in Houston, Texas, Valink raised $20.5 million total including an $11.8 million Pre-Series A in October 2025 to advance its pipeline into clinical trials.\n\nValink's pipeline centers on VLT-03 (targeting solid tumors in Phase I trials) and VLT-01 (targeting solid tumors with brain metastases, addressing the significant unmet need in CNS-penetrating oncology therapeutics). The ValiLinker conjugation technology enables precise drug-to-antibody ratios and reduces off-target toxicity that has historically limited ADC tolerability — the platform differentiates Valink from earlier ADC developers by addressing the conjugation chemistry precision that drives therapeutic index improvements in this modality.\n\nIn 2025, Valink competes in the ADC space with Seagen (acquired by Pfizer), ImmunoGen (acquired by AbbVie), Daiichi Sankyo (partnered with AstraZeneca), and numerous clinical-stage biotech ADC developers. ADC development has become one of the most active areas in oncology after the commercial success of Enhertu (trastuzumab deruxtecan) demonstrated the potential of the modality. Valink's site-specific conjugation differentiation targets the technical limitations of first-generation ADCs that created toxicity issues. The 2025-2026 strategy focuses on Phase I dose escalation for VLT-03, building clinical proof-of-concept for the ValiLinker platform, and positioning for partnership or licensing discussions with large pharma.
Nanterre global concessions and construction (EPA: DG, CAC 40) at €71.6B 2024 revenue record and €4.9B net income; 72 airports/4,400km toll roads with Edinburgh Airport acquisition competing with ACS for global infrastructure concessions.
About
VINCI SA is a Nanterre, France-headquartered global concessions and construction group — listed on Euronext Paris (EPA: DG) as a CAC 40 component — reporting record €71.6 billion in revenue and €4.9 billion in net income for 2024, employing 285,000 people across 120+ countries in three business divisions: Vinci Concessions (€11.7 billion revenue, operating 4,400 km of toll roads and 72 airports including Gatwick and Edinburgh airports in 14 countries), Vinci Energies (€27.5 billion revenue, energy transition and digital infrastructure services), and Vinci Construction (€31.8 billion revenue, civil engineering, buildings, and hydraulic engineering). International markets represent 58% of total revenue. CEO Xavier Huillard has led VINCI since 2010; Pierre Anjolras serves as incoming COO. Key acquisitions include ANA Aeroportos de Portugal (€3.08B, 2012), Gatwick Airport 50.01% (2019), ACS Industrial Services division (€5.2B, 2021), and Edinburgh Airport 50.01% (2024). Founded 1899 as Société Générale d'Entreprises.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.